Who can get a Covid booster this spring and what do private jabs cost?
Around 7.5 million people in England are eligible for a top-up vaccination.
Many pharmacies also sell the Covid jab privately.
Eligible members of the public in England can have a spring booster between 1 April to 17 June.
Vaccinations are being offered to:
adults aged 75 years and over
residents in a care home for older adults
people aged between six months and 74 years who have a weakened immune system and are at a greater risk from severe illness
Those who turn 75 years old between 1 April and 17 June 2025 can also have the jab.
NHS England says it is contacting everyone who qualifies by text, email, app message or letter.
However, those who qualify do not have to wait for an invitation and can visit the NHS website, use the NHS app or call 119 to book an appointment.
In different parts of the UK, the groups who qualify for a spring booster are the same but the dates of the campaign are slightly different:
Scotland: 31 March until 30 June
Wales: 1 April until 30 June
Northern Ireland: 7 April until 30 June
The NHS uses vaccines from two companies across the UK: Pfizer-BioNTech and Moderna.
People are advised to take whichever vaccine they are offered, as both provide protection against severe illness or death.
Data from the UK Health Security Agency - based on the 2024 spring vaccination programme - showed those who received a vaccine were more than 40% less likely to be admitted to hospital with Covid for up to two months after their jab, compared to those who did not receive one.
AstraZeneca pulled its Covid vaccine worldwide because of the surplus of updated vaccines from its competitors.
At the firm's request, in May 2024, the European Medicines Authority withdrew authorisation for the vaccine, which is no longer being manufactured or supplied.
A number of High Street chemists and private clinics sell and administer the Pfizer Covid vaccine directly to the public.
The cost per single dose varies but is typically between £75 and £99.
You need to be aged 12 or above, and must not have had a Covid vaccine in the previous three months. You also need to talk to a health professional to check that it is suitable.
A protein-based booster vaccine made by Novavax, which works differently to the Pfizer and Moderna jabs, is also available.
Moderna hopes to launch a combined flu and Covid vaccine later in 2025 or 2026, after the jab passed a vital part of final-stage scientific checks in June 2024.
Pfizer is also testing a similar two-in-one vaccine against flu and Covid.
If you have Covid, or think you might, the NHS recommends delaying vaccination until you feel better.
It also advises postponing if you have a high temperature or feel otherwise unwell with any illness.
However, there is no need to wait if you have recently recovered from Covid and feel well. The vaccines do not infect people with Covid, and cannot cause positive test results.
What to do if you have Covid
XEC Covid variant: What are the symptoms and is it spreading in the UK?
For most people, side effects are mild. The most common include a sore arm, headache, chills, fatigue and nausea.
They are part of the body's normal immune response to vaccination and tend to resolve themselves within a day or two.
Very rarely myocarditis - inflammation of the heart muscle - has been linked to the Moderna and Pfizer vaccines.
A very small number of people have experienced a severe allergic reaction after the Pfizer vaccine.
Patients with serious allergies should talk to their healthcare professional before being vaccinated.
Covid vaccine safety - What we know
Rise of vaccine distrust - why more of us are questioning jabs
Is the system letting down people who were harmed by Covid vaccines?
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 hours ago
- Yahoo
This Handwriting Change May Be An Early Sign Of Parkinson's
Parkinson's disease, the condition Ozzy Osborne was diagnosed with roughly five years before his death, affects about 153,000 people in the UK at the moment. It is a progressive neurological disease. While there is no single, outright cure for it yet, the NHS says therapies like medication and physiotherapy can minimise its symptoms for many. But sadly, the condition is often misdiagnosed, even though early diagnosis can be very beneficial. That's why organisations like Parkinson's UK champion better, earlier diagnoses, and hope one day for a single test that can accurately spot the disease as soon as possible. In the meantime, however, they've shared early signs of the condition; one of which involves changes to your handwriting. How is handwriting linked to Parkinson's? Parkinson's UK says that noticing smaller handwriting over time is one potential early sign. This is called micrographia, and could affect as many as 50-60% of people living with Parkinson's, though the numbers are not settled. 'You may notice the way you write words on a page has changed, such as letter sizes are smaller and the words are crowded together,' the charity shared. A 2022 paper suggested that the handwriting change may precede other motor symptoms of Parkinson's, like tremors. Parkinson's is not the only cause of handwriting changes – it's been linked to other neurological changes, while Parkinson's UK says 'writing can change as you get older, if you have stiff hands or fingers or poor vision' – but it may be worth seeing your doctor about it, especially if it comes with other symptoms. What are the other early symptoms of Parkinson's? According to Parkinson's UK, having a single early symptom doesn't mean you've got the disorder. But 'if you have more than one sign, you should consider making an appointment to talk to your doctor,' they wrote. Aside from micographia, the other possible symptoms they listed were: Tremors. Shaking in your finger, thumb, hand, or chin while at rest is a common early symptom. Loss of smell, especially for strongly-scented foods like bananas, liquorice, and gherkins. Moving a lot in your sleep, especially if you start acting out your dreams or thrashing around a lot. Trouble with movement or walking. You might find your arms don't swing as much as they used to when you walk, that your limbs or stiff, that your shoulders of hips feel tight, or that your feet feel 'stuck to the floor.' Constipation. This can be normal, but it can persist with Parkinson's. Developing a soft, low voice that others might describe as hoarse or breathy and which might sound quieter than usual. 'Facial masking,′ or a sad or angry expression on your face that happens regardless of your mood. Dizziness or fainting, for instance, when getting up out of a chair – this can be linked to low blood pressure, which is associated with Parkinson's. Stooping or hunching over, especially if this is new for you. Related... 'Super Smeller' Inspires Test To Spot Parkinson's 7 Years Before Diagnosis Gut Health Discovery Could Help Future Parkinson's Diagnoses Parkinson's Cases Are Set To Double By 2050. Here Are 5 Early Signs To Watch For
Yahoo
4 hours ago
- Yahoo
EMA Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Authorization of Moderna's COVID-19 mRNA Vaccine Targeting the SARS-CoV-2 Variant LP.8.1
Moderna's updated COVID-19 mRNA vaccine will be available for the 2025-2026 vaccination season, pending a European Commission authorization decision CAMBRIDGE, MA / / July 25, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending marketing authorization for an updated formulation of the COVID-19 vaccine Spikevax®, targeting the SARS-CoV-2 variant LP.8.1, for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals six months of age and older. Following the CHMP's positive opinion, the European Commission will make a marketing authorization decision on Moderna's updated COVID-19 vaccine for the 2025-2026 season. "The CHMP's positive opinion on our updated COVID-19 vaccine targeting the SARS-CoV-2 variant LP.8.1 is an important milestone in our ongoing effort to protect people across the European Union," said Stéphane Bancel, Chief Executive Officer of Moderna. "COVID-19 continues to place a significant burden on vulnerable populations and healthcare systems. Updated vaccines can be an important tool for protecting individuals and societies." The CHMP decision is based on a combination of manufacturing and preclinical data, as well as previous clinical, non-clinical and real-world evidence supporting the efficacy and safety of Moderna's COVID-19 vaccines. The updated vaccine composition aligns with guidance from various global health authorities, which have identified the LP.8.1 strain as an appropriate update to the COVID-19 vaccine composition for the 2025-2026 vaccination season. Additional regulatory applications for Moderna's updated COVID-19 vaccines targeting LP.8.1 are under review around the world. About Moderna Moderna is a leader in the creation of the field of mRNA medicine. Through the advancement of mRNA technology, Moderna is reimagining how medicines are made and transforming how we treat and prevent disease for everyone. By working at the intersection of science, technology and health for more than a decade, the company has developed medicines at unprecedented speed and efficiency, including one of the earliest and most effective COVID-19 vaccines. Moderna's mRNA platform has enabled the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. With a unique culture and a global team driven by the Moderna values and mindsets to responsibly change the future of human health, Moderna strives to deliver the greatest possible impact to people through mRNA medicines. For more information about Moderna, please visit and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube and LinkedIn. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding: the potential authorization by the European Commission of Moderna's COVID-19 vaccine targeting the SARS-CoV-2 variant LP.8.1; and the opportunity for Moderna to sell COVID-19 vaccines to up to 17 participating European Union countries over a four-year period. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna's control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include, among others, those risks and uncertainties described under the heading "Risk Factors" in Moderna's Annual Report on Form 10-K for the fiscal year ended December 31, 2024 and in subsequent filings made by Moderna with the U.S. Securities and Exchange Commission, which are available on the SEC's website at Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna's current expectations and speak only as of the date of this press release. Moderna Contacts Media:Clothilde CailletDirector, Country and Europe Communications Investors:Lavina TalukdarSenior Vice President & Head of Investor Relations+1 SOURCE: Moderna, Inc. View the original press release on ACCESS Newswire Sign in to access your portfolio
Miami Herald
4 hours ago
- Miami Herald
Oswaldo Muñoz, pioneer of Venezuelan community in Miami, dies after long illness
Oswaldo Muñoz, entrepreneur, editor, community leader and a key figure in the history of the Venezuelan diaspora in the United States, died on July 25 in Madrid at the age of 73 after a long battle with cancer. Founder of the community newspaper El Venezolano and later of El Venezolano TV, both based in Miami, Muñoz was a beloved and visionary figure who helped weave the first threads of unity among Venezuelans in South Florida, back when they were just beginning to arrive in the city in the early 1990s. He died as he lived: discreetly, surrounded by the love of those closest to him, and faithful to his nature of shielding others from his own suffering. 'He didn't want anyone to know what he was going through,' said Ignacio Marcano, one of his closest companions during his final days. 'He would tell people he was just getting some tests done. He never wanted to worry anyone.' After Muñoz's final hospital visit, his doctors decided to sedate him. He passed away peacefully at 7 am local time in Madrid. Pioneer in unknown territory Oswaldo arrived in Miami in 1991, at a time when the Venezuelan community was so small that, as he liked to say, 'we could all fit in a restaurant dining room.' He founded El Venezolano in August 1992, just days after the devastating impact of Hurricane Andrew on South Florida. Against all odds, he managed to distribute the first edition amid the hurricane's devastation. From then on, El Venezolano became a beacon for thousands of newly arrived Venezuelans seeking news, guidance and a voice to represent them in exile. What began as a modest entrepreneurial venture turned into an influential media outlet with franchises in other U.S. cities and across Latin America. 'Oswaldo was the Venezuelan who brought Venezuelans and the local Miami community together the most,' said José Hernández, a friend and colleague who led the editorial team at El Venezolano for years. 'He was one of the first visible leaders at a time when there were hardly any Venezuelans in the city. He shared spaces with figures like Jorge Mas Canosa and other important community leaders.' More than just a paper For years, El Venezolano served as an extension of the Venezuelan consulate, especially when the official representation ceased operating in Miami. 'On many occasions, we functioned as the consulate,' recalls Sylvia Bello, Muñoz's business partner, friend and colleague for 25 years. 'Oswaldo was a man who supported so many people in every way.' The paper became a platform for employment, integration and gathering. 'He gave work to a lot of people,' Bello said. 'He organized events that brought together hundreds. At our anniversary editions, we hosted as many as 600 people in Miami's most prestigious hotels. Those were celebrations that showcased the strength and pride of our community.' Between 1998 and the years leading up to the COVID-19 pandemic, El Venezolano was an undisputed reference point—not only for its content but also for the approachable and charismatic style of its founder. Muñoz had a natural ability to connect with public figures and celebrities, his colleagues said. 'He was friends with everyone: El Puma (José Luis Rodríguez), the Stefans (Gloria and Emilio), you name it. He wasn't afraid of anything. He'd pick up the phone and everyone would answer,' Bello recalled. Those who knew him agree that behind the editor was a deeply generous person, always ready to help. 'He was the friend everyone wants to have—unconditional, compassionate, always smiling,' Bello added. For many immigrants arriving without support networks, without jobs, and without any idea of how to begin anew in a foreign city, Oswaldo was a guide and anchor. 'There was no one who approached him for help and didn't receive it,' Hernández said. 'In a way, he helped the city grow. Many people advertised with him, and many businesses started thanks to El Venezolano.' In a story he proudly shared, Oswaldo recounted meeting Nobel-prize winning novelist Gabriel García Márquez at a book fair in Bogotá. The Colombian writer complimented his writing. Oswaldo humbly replied that he wasn't a journalist by profession. García Márquez responded: 'You're wrong. Journalism is a craft, not a profession.' Few lines could have better described Muñoz's path. Without a university degree in journalism, he built a career based on vocation, instinct, empathy and an ability to connect with people. Enduring legacy Muñoz's legacy cannot be measured solely in printed issues or TV broadcasts. His greatest contribution, those close to him said, is the community he helped build. 'He fulfilled all his dreams,' says Sylvia Bello. 'Now he's in a better place, and he left a mark on each of us who knew him.' Over the last three years, Oswaldo waged a tough battle with cancer. It started in his spine, then moved to his lungs. Later, doctors needed to remove a kidney. Despite everything, he managed to recover multiple times. 'He always had this amazing ability to bounce back. I don't know how he did it,' Bello says. 'But eventually, his body said, 'This is it.'' Despite his deteriorating health, he tried to maintain life as normal as possible, those close to him said. Muñoz leaves behind a grateful community, dozens of friends, former coworkers, readers, and partners who considered him family, his friends said. He also leaves behind a body of work that will live on through the pages of El Venezolano and in the memories of those whose lives he touched. He was, in the words of those who knew and admired him, 'the unconditional friend everyone hopes to have,' perhaps the best headline to remember his life by.
